« Return to News | Clinical Intelligence

HemaQuest raises $13 million for phase IIb study of sickle cell disease

Monday, March 12, 2012 03:49 PM

HemaQuest Pharmaceuticals, a biotechnology company focused on developing small molecule therapeutics to treat hemoglobin disorders, has closed a $13 million extension of its Series B financing.

The Series B extension is being funded by HemaQuest’s existing investors: Aberdare Ventures, De Novo Ventures, Forward Ventures, Latterell Venture Partners and Lilly Ventures. Proceeds from the financing will be used to fund a randomized, double-blind, placebo-controlled phase IIb clinical study evaluating lead product candidate HQK-1001 in patients with sickle cell disease. HemaQuest believes this financing, combined with existing cash balances, will be sufficient to allow completion of the trial and to fund operations through early 2014.

HQK-1001 has been shown to stimulate fetal hemoglobin expression and red blood cell production in the laboratory, reducing the frequency of pain crises and hospitalizations of patients with sickle cell disease. It has received Orphan Drug designation in the U.S. and Europe for both sickle cell disease and beta thalassemia.

“We are extremely pleased to have the continuing support of our existing investors,” said John P. Longenecker, Ph.D., CEO of HemaQuest. “This additional financing enables us to continue our HQK-1001 clinical development program for sickle cell, moving another step closer to a new therapy for this devastating disease affecting underserved populations around the world.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.